Chris Boshoff: FDA Approves Our Treatment for Hemophilia A and B for 2 New Patient Populations
Chris Boshoff, Chief Scientific Officer and President of Research and Development at Pfizer, shared on LinkedIn:
”The FDA has approved our treatment for hemophilia A and B for two new patient populations following a priority review.
With this approval, children ages 6 to 11 with hemophilia B will have a subcutaneous, non-factor treatment option available for the first time.
Bringing a medicine discovered and developed by Pfizer to the people who need it most—guided at every step by patient need—is an important moment for our teams.
A special thank you to the Pfizer scientists who are continuing to advance care for people with hemophilia, and to the hemophilia patient community who participated in clinical trials that are instrumental to making advancements like this one happen.”
Proceed to the video attached to the post.
Stay updated with Hemostasis Today.
-
Jun 11, 2026, 16:46Moaz Abouelmagd: Key Findings from a Large Network Meta-Analysis of IV Thrombolytics in Acute Ischemic Stroke
-
Jun 11, 2026, 16:37Wolfgang Miesbach: From Failed Intravitreal Trials to Real Benefit – Subretinal AAV8 Gene Therapy in Pediatric X-Linked Retinoschisis
-
Jun 11, 2026, 16:34Joao Mariano Pego: Advancing Coagulation Diagnostics Through Standardized Thrombin Generation
-
Jun 11, 2026, 16:33Ifeanyichukwu Ifechidere: Nobody Talks About Thrombosis in Sickle Cell Disease
-
Jun 11, 2026, 16:31Karim Mahawish: Ischaemic Stroke Despite Anticoagulation in Atrial Fibrillation
-
Jun 11, 2026, 16:29Salim Virani: The 2026 ACC/AHA Multisociety Dyslipidemia Guideline Promotes Early Prevention
-
Jun 11, 2026, 16:25Toyosi Onwuemene: What Clinicians Reveal About Bleeding and Clotting Care
-
Jun 11, 2026, 16:20Tejas Ahire: Rh Incompatibility – A Small Blood Group Difference with Big Clinical Impact
-
Jun 11, 2026, 16:19Jack Shuang Hou: Bayer Advances Asundexian as EMA Reviews New Option for Preventing Recurrent Ischemic Stroke